Content
All Posts > Content under Healthcare
6 ETF Picks For September
Article By:
Zacks Investment Research
Read
Wednesday, September 6, 2017 6:44 AM EDT
The Euro zone economic growth has looked up this year. The region grew 0.6% sequentially in Q2 following 0.5% expansion in the previous period. Despite this positive sentiment, a rising euro might be a deterrent.
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By:
Rod Raynovich
Read
Tuesday, September 5, 2017 11:08 PM EDT
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
Biotech Digest – INSM Reports Positive Data, MRK Gets EC Approval, LCI Receives FDA Approval
Article By:
KKD Healthcare Analytics
Read
Tuesday, September 5, 2017 11:32 AM EDT
Oramed Pharmaceuticals reported the successful conclusion of its meeting with the FDA with regard to its drug candidate ORMD-0801. Insmed (INSM) stock jumped over 100 percent in the pre-market session.
Finally… A Cure For Cancer?
Article By:
Marc Lichtenfeld
Read
Monday, September 4, 2017 5:31 PM EDT
Novartis’ CAR-T therapy Kymriah got the green light from U.S. regulators to treat children and young adults with B-cell acute lymphoblastic leukemia who aren’t responding to other more conventional treatments.
Congressman Supporting Approval Of PTC's DMD Treatment, Says Citi
Article By:
The Fly
Read
Monday, September 4, 2017 3:34 PM EDT
Citi analyst Joel Beatty found comments online from U.S. Congressman Collin Peterson that voice support for approval of PTC Therapeutics' Duchenne muscular dystrophy treatment ataluren, which is also known as Translarna.
In this article: PTCT
4 Large-Cap Medical Device Stocks To Buy Amid Political Woes
Article By:
Zacks Investment Research
Read
Monday, September 4, 2017 2:52 PM EDT
The MedTech industry is looking forward to the abolishment of the major healthcare taxes including Cadillac tax and the 2.3% MedTech tax. Although the Republicans failed to pass the skinny repeal it has been able to delay the Cadillac tax until 2026.
Opiant Phamaceuticals - Chart Of The Day
Article By:
Jim Van Meerten
Read
Friday, September 1, 2017 12:09 PM EDT
The Chart of the day belongs to Opiant Pharmaceuticals. Since the Trend Spotter signaled a buy in 7/6 the stock gained 41.88%.
In this article: OPNT
Biotech Digest – IMDZ Reports Data, JNJ Terminates Collaboration
Article By:
KKD Healthcare Analytics
Read
Friday, September 1, 2017 11:46 AM EDT
Immune Design announced interim top line data from a Phase 2 clinical trial assessing the combination of its CMB305 and Roche's Tecentriq (atezolizumab) compared to Tecentriq alone in 88 soft tissue sarcoma patients.
3 Canadian Licensed Producers Capitalizing On Cannabis Oil
Article By:
Technical420
Read
Thursday, August 31, 2017 2:52 PM EDT
Cannabis oil is a significant revenue stream for licensed producers in Canada and this is a trend we expect to continue for the foreseeable future. Cannabis oil represents a fantastic opportunity and solution for licensed producers.